Finance

Beta
Ask
Lists
MRSH:NYSE
Marsh & McLennan Companies Inc
$163.84
+2.33%
(+3.73) 1D
$163.84
0.00% (0.00)
After hours
Closed: Jun 23, 4:00:07 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MRSH...
Open
$162.07
High
$164.66
Low
$161.80
Mkt. cap
77.14B
Avg. vol.
2.82M
Volume
2.59M
52-wk high
$193.32
52-wk low
$156.60
Beta
0.62
Shares outstanding
481.80M
No. of employees
95K
Open
$162.07
High
$164.66
Low
$161.80
Mkt. cap
77.14B
Avg. vol.
2.82M
Volume
2.59M
52-wk high
$193.32
52-wk low
$156.60
Beta
0.62
Shares outstanding
481.80M
No. of employees
95K
News stories
From sources across the web
Profile
Marsh & McLennan Companies, Inc., doing business as Marsh McLennan and Marsh, is a global professional services firm headquartered in New York City, with businesses in insurance brokerage, risk management, reinsurance services, talent management, investment advisory, and management consulting. Its four main operating companies are Marsh, which offers risk management, insurance broking, insurance program management, risk consulting, analytical modeling, and alternative risk financing services; Marsh Re, a reinsurance intermediary and advisor; Mercer, which provides consulting to employers for health insurance, retirement plans, and pension plans; and Oliver Wyman, including Lippincott and NERA Economic Consulting, which provides consulting services. In 2024, risk and insurance services contributed a total of 63% of revenues and 71% of operating profit, while consulting contributed 37% of revenues and 29% of operating profit. It is the largest insurance broker worldwide. The company is ranked 175th on the Fortune 500 and 267th on the Forbes Global 2000. Wikipedia
About Marsh & McLennan Companies Inc
CEOJohn Q. Doyle
Employees95K
Founded1905
HeadquartersNew York, New York, United States
SectorInsurance
Websitemarshmclennan.com
Analyst Ratings
Based on 16 analysts giving stock ratings to MRSH in the past 3 months
Buy
Buy
6
Hold
9
Sell
1
12 month forecast
Based on 16 Wall Street analysts offering 12 month price targets for MRSH in the last 3 months.
Highest
Current $163.84
$245.00 (+49.54%)
Average
$199.88 (+22.00%)
Lowest
$174.00 (+6.20%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Brian Meredith
UBS
Buy
Reiterated
$203.00
+23.9%
06/09/2026
Harry Fong
Roth MKM
Hold
Reiterated
$200.00
+22.1%
06/08/2026
Elyse Greenspan
Wells Fargo
Hold
Maintained
$186.00
+13.5%
05/26/2026
Paul Newsome
Piper Sandler
Hold
Maintained
$182.00
+11.1%
05/26/2026
Bob Huang
Morgan Stanley
Hold
Maintained
$180.00
+9.9%
05/21/2026
Matthew Heimermann
Citi
Buy
Upgraded
$200.00
+22.1%
05/06/2026
Robert Cox CFA
Goldman Sachs
Buy
Upgraded
$200.00
+22.1%
05/06/2026
David Motemaden
Evercore ISI
Buy
Maintained
$236.00
+44%
04/17/2026
Michael Zaremski
BMO Capital
Hold
Maintained
$245.00
+49.5%
04/17/2026
Meyer Shields
KBW
Hold
Maintained
$203.00
+23.9%
04/17/2026
Rowland Mayor
RBC Capital
Hold
Maintained
$200.00
+22.1%
04/16/2026
Alex Scott
Barclays
Buy
Maintained
$206.00
+25.7%
04/17/2026
Yaron Kinar
Mizuho Securities
Hold
Maintained
$194.00
+18.4%
04/17/2026
Adam Klauber
William Blair
Hold
Maintained
$183.00
+11.7%
04/16/2026
Joshua Shanker
Bank of America Securities
Sell
Maintained
$174.00
+6.2%
04/14/2026
Pablo Singzon
J.P. Morgan
Buy
Maintained
$206.00
+25.7%
04/09/2026
Jimmy Bhullar
J.P. Morgan
Buy
Reiterated
$226.00
+37.9%
03/05/2026
Gregory Peters
Raymond James
Buy
Upgraded
$225.00
+37.3%
02/17/2026
Ryan Tunis
Cantor Fitzgerald
Buy
Maintained
$212.00
+29.4%
02/02/2026
Last report
Apr 16, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$3.29 / $3.22
+2.14%beat
Revenue / Est. (USD)
7.60B / 7.40B
+2.69%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
6.97B
6.35B
6.60B
7.60B
Cost of goods sold
3.85B
3.84B
3.78B
4.05B
Cost of revenue
3.85B
3.84B
3.78B
4.05B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
-
Operating expense
1.25B
1.29B
1.13B
1.70B
Total operating expenses
5.10B
5.13B
4.92B
5.75B
Operating income
1.88B
1.22B
1.68B
1.85B
Other non operating income
-
-
-
-
EBT including unusual items
1.65B
1.01B
1.06B
1.58B
EBT excluding unusual items
1.65B
1.01B
1.46B
1.63B
Income tax expense
415.00M
253.00M
222.00M
395.00M
Effective tax rate
25.21%
25.05%
21.02%
24.98%
Other operating expenses
1.25B
1.29B
1.13B
1.70B
Net income
1.21B
747.00M
821.00M
1.15B
Net profit margin
17.36%
11.76%
12.45%
15.08%
Earnings per share
2.72
1.85
2.12
3.29
Interest and investment income
12.00M
25.00M
21.00M
17.00M
Interest expense
-243.00M
-237.00M
-235.00M
-240.00M
Net interest expenses
-231.00M
-212.00M
-214.00M
-223.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.11B
1.45B
1.91B
2.08B
Gain or loss from assets sale
-15.00M
-2.00M
4.00M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer